IMPORTANCE Elevated blood lead level is associated with serious, often irreversible, health consequences.
L ead causes a number of adverse health effects primarily affecting the central nervous, hematopoietic, hepatic, and renal systems. 1 Many health effects associated with chronic exposure to elevated blood lead levels are irreversible, with the nervous system being the most important. 1 The severity of lead toxicity is correlated with higher blood lead levels, but manifestations may vary. Elevated blood lead levels in children are associated with IQ deficits, attention-related behaviors, and poor academic achievement. 2, 3 Lead exposure during pregnancy is associated with spontaneous abortion, 4 reduced fetal growth, premature birth, blood pressure elevation, 5 and cognitive deficiencies in the child. 4 Elevated blood lead level is defined as greater than 5 μg/dL, according to the Centers for Disease Control and Prevention (CDC). 3 Reference ranges are based on population levels from the National Health and Nutrition Examination Survey blood lead distribution; these do not define safe lead levels but are the level at which further clinical monitoring and treatment is recommended. The reference range may change with population prevalence.
In 2006, the US Preventive Services Task Force (USPSTF) found insufficient evidence for screening asymptomatic children at increased risk for elevated blood lead levels (I statement) and recommended against routine screening in asymptomatic pregnant women and children aged 1 to 5 years at average risk (D recommendations). 6 Recommendations of other organizations are summarized in eTables 1 and 2 in the Supplement. This systematic review was commissioned by the USPSTF to update the prior review 7 by synthesizing evidence on the benefits and harms of screening for elevated blood lead levels in asymptomatic pregnant women and children 5 years and younger.
Methods

Scope of the Review
Using established methods, 8 this review addressed key questions (KQs) as shown in the analytic framework in Figure 1 and Figure 2 . Methodological details, including study selection, search strategies, excluded studies, data analysis methods, and detailed results are available in the full evidence report at http:// www.uspreventiveservicestaskforce.org/Page/Document/ UpdateSummaryFinal/elevated-blood-lead-levels-in-childhoodand-pregnancy-screening.
9,10
Data Sources and Searches
Cochrane CENTRAL, the Cochrane Database of Systematic Reviews (through June 2018), and Ovid MEDLINE (1946 to June 2018) were searched, including all studies from prior reviews and reference lists of included studies. 7 Since June 2018, we continued to conduct ongoing surveillance through article alerts and targeted searches of high-impact journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and therefore the related USPSTF recommendation. The last surveillance was conducted on December 5, 2018, and identified no relevant new studies. Search strategies are listed in eAppendix 1 in the Supplement.
Study Selection
Populations of asymptomatic children 5 years and younger and asymptomatic pregnant women were included, regardless of risk for elevated blood lead levels. Testing approaches included studies of screening questionnaires and venous or capillary blood lead testing. Comparisons for KQ1 were screening vs no screening; for KQ2a, a questionnaire against a reference standard (ie, venous lead level); for KQ2b, capillary vs venous blood lead level testing; and for treatment questions, treatment vs no treatment, placebo, or inactive control. Intermediate outcomes (eg, blood lead levels) were included, as well as clinical outcomes using validated measures of cognitive or neurobehavioral outcomes in children. Other outcomes were measures of diagnostic accuracy (KQ2) and harms of testing (eg, anxiety, distress, pain, or discomfort related to testing) and treatment. English-language articles were eligible for inclusion. Included studies were randomized clinical trials (RCTs), nonrandomized controlled intervention studies, and observational studies (for questions on screening and treatment); studies on the diagnostic accuracy of screening questionnaires or capillary sampling; and trials and observational studies of harms. Studies conducted in countries with a "very high" Human Development Index 11 that evaluated interventions that focused on the individual or family (ie, counseling, nutritional interventions, residential hazard control techniques, and chelation therapy) were included. Studies of policies, laws, or communitybased interventions focused on primary prevention of lead exposure were excluded.
level of 10 μg/dL or greater as the reference standard. Five studies evaluated the accuracy of the 1991 CDC questionnaire and 4 evaluated modified versions of the CDC questionnaire for specific populations and settings. [15] [16] [17] [18] [19] [20] [21] [22] [23] The CDC questionnaire is a 5-question survey developed in 1991 that aims to assess residential, household, occupational, and personal risk factors for lead exposure in children. Sample sizes ranged from 167 to 2978 (total n = 6873). Where reported, mean age range was 9 to 31 months. 18, 19 Seven studies were conducted in urban or suburban communities, and 3 studies were from rural communities. Two studies identified the population as high risk 16, 23 and others did not specify risk Is there direct evidence that screening for elevated blood lead levels in asymptomatic children age 5 years and younger improves health outcomes (ie, reduced cognitive or behavioral problems or learning disorders)?
What is the accuracy of capillary blood lead testing in children?
Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy improve health outcomes in asymptomatic children with elevated blood lead levels?
5
What are the harms of interventions in asymptomatic children with elevated blood lead levels? 6 Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy reduce blood lead levels in asymptomatic children with elevated blood lead levels? Evidence reviews for the US Preventive Services Task Force (USPSTF) use an analytic framework to visually display the key questions (KQs) that the review will address to allow the USPSTF to evaluate the effectiveness and safety of a preventive service. The questions are depicted by linkages that relate interventions and outcomes. A dashed line depicts a health outcome that follows an intermediate outcome. Refer to the USPSTF Procedure Manual for further details. 8 a Interventions include counseling families to reduce lead exposure, nutritional interventions, residential hazard control techniques, and chelation therapy. b Included outcomes measured in family members (eg, siblings, pregnant women in the same household) subsequently identified as having elevated blood lead levels after the index family member was found to have an elevated blood lead level during screening.
level; however, many of the populations surveyed were from public programs, such as Medicaid or public health clinics. The prevalence of blood lead level 10 μg/dL or greater ranged from 0.6% 15 to 29%.
15
All studies were rated fair quality. Methodological shortcomings included unclear enrollment methods and exclusion of some patients from analysis. One poor-quality retrospective study was excluded from this analysis and was not included in the total number of studies.
25
Five studies (n = 2265) conducted in mostly urban settings reported sensitivity of the CDC questionnaire that ranged from 32% to 83% and specificity that ranged from 32% to 80% (Table 1 ). The pooled sensitivity was 48% (95% CI, 31%-66%) and the pooled specificity was 58% (95% CI, 39%-74%) ( Figure 5) Two studies from urban settings had poor accuracy (sensitivity, 57%-68%; specificity, 51%-58%) for identifying children with elevated blood lead levels (Table 1) . 17, 18 Two studies conducted in rural settings 20, 22 found that the adapted questionnaires had low accuracy (sensitivity, 25%; specificity, 49%) for detecting children with elevated blood lead levels (Table 1) .
Diagnostic Accuracy of Capillary Blood Lead Testing in Children
Key Question 2b. What is the accuracy of capillary blood lead testing in children? Four fair-quality cohort studies assessed the diagnostic accuracy of capillary testing compared with venous sampling for elevated blood lead levels ( Table 2) .
26-28,30 All 4 studies were conducted in the urban United States and were published between 1994 and 1998. Sample sizes ranged from 124 to 513 (total n = 1431). Female participants comprised 41% to 47% of the sample in 3 studies; the fourth study did not report sex. Two studies predominately enrolled black children, 26,30 and 1 study evaluated a more diverse study population (38% white, 28% black, 21% Hispanic, and 6% Asian 27 ); the fourth study did not report race or ethnicity. 28 Among the 3 studies reporting baseline lead levels, the proportion of children 
Key questions
Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy improve health outcomes in asymptomatic pregnant women with elevated blood lead levels?
5
Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy reduce blood lead levels and rates of gestational hypertension in asymptomatic pregnant women with elevated blood lead levels?
4
What are the harms of interventions in asymptomatic pregnant women with elevated blood lead levels? 6
What is the accuracy of questionnaires or clinical prediction tools that identify pregnant women who have elevated blood lead levels? 2 b. Does the effectiveness of screening in asymptomatic pregnant women vary by gestational age? a. Is there direct evidence that screening for elevated blood lead levels in asymptomatic pregnant women improves health outcomes (ie, reduced cognitive problems in offspring, adverse perinatal outcomes, and adverse maternal outcomes)?
1
What are the harms of screening for elevated blood lead levels (with or without screening questionnaires) in asymptomatic pregnant women? 3 
5
Evidence reviews for the US Preventive Services Task Force (USPSTF) use an analytic framework to visually display the key questions (KQs) that the review will address to allow the USPSTF to evaluate the effectiveness and safety of a preventive service. The questions are depicted by linkages that relate interventions and outcomes.
a Interventions include counseling families to reduce lead exposure, nutritional interventions, residential hazard control techniques, and chelation therapy. b Included outcomes measured in family members (eg, siblings, pregnant women in the same household) subsequently identified as having elevated blood lead levels after the index family member was found to have an elevated blood lead level during screening. with blood lead level 10 μg/dL or greater ranged from 21% to 31%. [26] [27] [28] Methodologic shortcomings included unclear enrollment methods and exclusion of some patients from analysis. Three of 4 studies reported diagnostic accuracy of capillary sampling at a blood lead level cutoff of 10 μg/dL or greater (n = 1136) ( Table 2 ). Sensitivities ranged from 87% to 91% and specificities ranged from 92% to 99%. [26] [27] [28] For a blood lead level cutoff of 15 μg/dL or greater, 3 studies (n = 1136) reported sensitivities ranging from 36% to 83% and specificities from 95% to 98%. [26] [27] [28] For a blood lead level cutoff of 20 μg/dL or greater, 3 studies (n = 918) reported sensitivities ranging from 78% to 96% and specificities from 91% to 100%. 26, 27, 30 One study (n = 295) evaluated different preparation methods for capillary blood sampling. 30 Using a capillary sampling threshold of greater than 20 μg/dL, the most commonly used sampling method (ie, soap and water plus alcohol) had the highest specificity (100%) compared with the other methods and similar sensitivity (88%) ( Table 2 ).
Harms of Screening
Key Question 3. What are the harms of screening for elevated blood lead levels (with or without screening questionnaires) in children? No studies evaluated the harms of screening vs not screening children for elevated blood lead levels.
Effectiveness of Interventions to Reduce Blood Lead Levels
Key Question 4. Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy reduce blood lead levels in asymptomatic children with elevated blood lead levels?
Seven RCTs 31-40 (reported in 10 publications) evaluated the effects of interventions to reduce blood lead concentrations in asymptomatic children with elevated blood lead levels ( Table 3) . Two studies evaluated chelation, 3 studies evaluated home abatement, and 2 evaluated nutritional supplementation. Sample sizes ranged from 39 to 780 (total n = 1419). Mean age of participants was 1.6 to 3.6 years, with balanced sex distributions in the 3 studies that reported sex. One study was rated good quality, 4 fair quality, and 2 poor quality. Methodological limitations in the poor-quality studies included high loss to follow-up or failure to describe randomization, allocation concealment, or masking methods.
Chelation
Two trials (n = 819) found inconsistent effects of dimercaptosuccinic acid (DMSA) chelation therapy on blood lead level in asymptomatic children with baseline levels of 20 to 45 μg/dL (Table 3) . 31, 34, 35, 37, 38 Duration of follow-up was 6 years in 1 trial and 6 months in the other. The Treatment of Lead-Exposed Children (TLC) study, a goodquality RCT (n = 780), evaluated children aged 12 to 33 months with blood lead levels between 20 and 44 μg/dL. 31 or placebo and could be treated up to 3 times with a goal blood lead concentration of less than 15 μg/dL. DMSA was associated with a blood lead level at 1 week that was mean difference of 11 μg/dL lower than that of children in the placebo group (Table 3) . However, blood lead levels increased once DMSA was discontinued, and at 52 weeks the blood lead level for the treatment group was only a mean difference of 2.7 μg/dL lower than that of the placebo group (95% CI, 1.9-3.5 μg/dL). 38 In a follow-up study of 7-year-old TLC study participants (83% of original study population) 4.5 to 6 years after treatment, mean levels were similar in both groups (8.0 μg/dL).
34
A small, fair-quality study (n = 39) 37 randomized children aged 2.5 to 5 years with mean blood lead level between 30 and 45 μg/dL to 1 course of DMSA or control. DMSA was dosed according to weight and was administered 3 times daily for 5 days followed by twice daily for 14 days. There were no significant differences in mean blood lead level at 1 month (27. Table 3) .
Nutritional Interventions
Two poor-quality studies provided insufficient evidence to determine the effects of calcium or iron nutritional supplementation interventions on blood lead level in children.
36,39
Residential Lead Hazard Control Techniques
Three fair-quality RCTs found no clear effects of home lead abatement in lowering blood lead concentrations in asymptomatic children with elevated blood lead levels at baseline (Table 3) . 32,33,40 One trial (n = 175) randomized children younger than 28 months in Rhode Island with blood lead levels of 15 to 19 μg/dL 33 to a home-based intervention or control. Blood lead levels in both groups decreased overall, but there was no significant difference between the intervention and control groups at 3, 6, or 12 months after baseline. A fair-quality trial (n = 90) 32 randomized age-matched pairs of 12-to 60-monthold children with mean blood lead levels 15 to 30 μg/dL to home remediation and lead abatement or delayed intervention for 1 year. Despite reductions in home lead concentrations after the intervention, the effects of remediation on mean blood lead levels were small (17.5 vs 17.9 μg/dL; mean change, 1% [95% CI, −11% to 11%]), with no significant difference between groups. A fair-quality trial (n = 84) 40 conducted in Florida enrolled asymptomatic children from the Women, Infants, & Children and Head Start programs with blood lead levels 3 to 10 μg/dL (mean, 5.29 μg/dL [range, 3.0-9.3 μg/dL]). Participants were randomized to receive an educational brochure, a home cleaning kit, or a formal home inspection and abatement. A passive control group received no intervention or information. All groups experienced a decrease in blood lead level of 2.26 to 2.99 μg/dL over 6 to 12 months, with no significant difference between groups.
Effectiveness of Interventions to Improve Health Outcomes
Key Question 5. Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy All childhood studies were fair quality; the pregnancy study was poor quality. Quality was assessed using criteria outlined in the US Preventive Services Task Force Procedure Guide. improve health outcomes in asymptomatic children with elevated blood lead levels?
The TLC 34,35,38 trial of DMSA chelation therapy vs placebo (n = 780) was the only study to evaluate the effect of interventions for lowering elevated blood lead level on health outcomes by measuring children's neuropsychological outcomes (Table 3) . At 36 months, there were no significant differences between chelation therapy and placebo in the Wechsler Preschool and Primary Scale of Intelligence-Revised, the Developmental Neuropsychological Assessment (NEPSY), or the Conners Parent Rating Scale-Revised. In a follow-up study 34 of the same children at age 7 years (4.5-6 years after treatment), chelation was associated with lower (worse) scores on the adjusted Attention and Executive Functions subscore of the NEPSY (unadjusted difference, −1.8 [95% CI, −4.5 to 1.0]; adjusted P = .045). There were no statistically significant effects on any other cognitive, neuropsychiatric, or behavioral outcome.
Harms of Interventions for Children With Elevated Blood Lead Levels
Key Question 6. What are the harms of interventions in asymptomatic children with elevated blood lead levels? One good-quality RCT (Table 3 ) and 1 poor-quality study reported adverse effects of chelation therapy. The TLC trial (n = 780) compared DMSA chelation therapy with placebo in children aged 12 to 33 months with blood lead concentrations between 20 and 44 μg/dL. 38 
Screening and Treatment in Pregnancy
Evidence to determine effects of lead screening during pregnancy was extremely limited. There were no studies of screening in pregnant women and no studies reported health outcomes of interventions to reduce blood lead levels in asymptomatic pregnant women. One study reported the diagnostic accuracy of a clinical questionnaire for pregnant women, 24 and 1 study reported effects of a nutritional intervention during pregnancy.
41
Effectiveness of Screening Key Question 1a. Is there direct evidence that screening for elevated blood lead levels in asymptomatic pregnant women improves health outcomes (ie, reduced cognitive problems in offspring, adverse perinatal outcomes, and adverse maternal outcomes)? Key Question 1b. Does the effectiveness of screening in asymptomatic pregnant women vary by gestational age? No studies directly evaluated clinical benefits and harms of screening pregnant women for elevated blood lead levels vs no screening or how effectiveness of screening varies according to the gestational age at which screening is performed.
Diagnostic Accuracy of Questionnaires or Clinical Prediction Tools
Key Question 2. What is the accuracy of questionnaires or clinical prediction tools that identify pregnant women who have elevated blood lead levels?
One fair-quality observational study 24 evaluated the accuracy of a questionnaire for identifying pregnant women with elevated blood lead levels using 4 questions from the 5-question 1991 CDC questionnaire designed to identify children at risk (n = 314). Women with a positive response to at least 1 of the 4 questions were more likely to have elevated blood lead levels than those who answered negatively to all 4 questions (relative risk, 2.39 [95% CI, 1.17 to 4.89]; P = .01) ( Table 1) . However, diagnostic accuracy was poor, with a sensitivity of 75.7% and specificity of 46.2%. The single most predictive item was having a "home built before 1960."
Harms of Screening
Key Question 3. What are the harms of screening for elevated blood lead levels (with or without screening questionnaires) in asymptomatic pregnant women? No study directly compared the harms of screening pregnant women for elevated blood lead levels in a screened vs an unscreened population. 
Effectiveness of Interventions to Reduce Blood Lead Levels and Gestational Hypertension
Key Question 4. Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy reduce blood lead levels and rates of gestational hypertension in asymptomatic pregnant women with elevated blood lead levels? One fair-quality RCT (n = 670) of healthy pregnant women (mean baseline lead level, ≈4 μg/dL) in Mexico found calcium supplementation associated with reduced blood lead levels vs placebo (difference, 11%; P = .004; levels in each group not reported) ( Table 3) . 41 Effects were more pronounced in women with baseline blood levels of 5 μg/dL or greater. Women were not required to have elevated blood levels at baseline. Limitations included unclear allocation methods, unblinded design, and some baseline betweengroup differences, including dietary calcium intake. Loss to follow-up was 14% (46/334) in the calcium group and 18% (59/336) in the placebo group. No harms were reported.
Effectiveness of Interventions to Improve Health Outcomes
Key Question 5. Do counseling and nutritional interventions, residential lead hazard control techniques, or chelation therapy improve health outcomes in asymptomatic pregnant women with elevated blood lead levels?
No studies reported health outcomes after interventions to reduce blood lead levels in asymptomatic pregnant women.
Harms of Interventions for Pregnant Women With Elevated Blood Lead Levels
Key Question 6. What are the harms of interventions in asymptomatic pregnant women with elevated blood lead levels?
One RCT on the effects of calcium supplementation on blood lead levels in pregnant women did not report harms (Table 3) . 41 Discussion A summary of the evidence for this updated review is shown in Table 4 and Table 5 (summary of evidence tables from the full USPSTF reports are available in eTables 6 and 7 in the Supplement). Consistent with the prior USPSTF review, 7 no evidence was found that directly evaluated benefits or harms of screening children for elevated blood lead levels compared with no screening. Based on studies available at the time of the prior USPSTF review, instruments to identify children at higher risk of elevated blood levels to guide targeted screening have poor diagnostic accuracy. This update confirms there are no clear effects of interventions for lowering elevated blood levels in affected children or to improve neurodevelopmental outcomes. Evidence to determine benefits and harms of screening or treating elevated lead levels during pregnancy remains extremely limited. Given the decreased prevalence of elevated blood lead levels identified in the US pediatric population (from 88% between 1976 and 1980 to 0.8% from 2007 to 2010), targeted screening strategies have been suggested. 2 The most commonly used risk assessment instrument is the CDC questionnaire; however, studies of this instrument or adapted versions have found poor diagnostic accuracy, with results that are not informative. 17, 18, 20, 22, 43 Furthermore, the CDC questionnaire was created in 1991 and no study on its accuracy has been published since 1997, potentially limiting the applicability of available There is limited evidence on the effectiveness of interventions for elevated blood lead levels on neurodevelopmental outcomes and longer-term blood lead levels. One trial showed short-term (through 1 year) effects of DMSA chelation on lowering blood levels vs placebo in children with moderately elevated blood levels (20-44 μg/dL) at baseline, but no clear effects on longer-term lead levels or neurodevelopmental outcomes, with some data indicating potential harms. 38 No trial evaluated effects of chelation in children with blood lead levels less than 20 μg/dL, but chelation is not recommended at this level in the absence of severe symptoms. Evidence on residential interventions was limited and showed no clear effects on blood lead concentrations. Evidence on calcium and iron nutritional interventions was poor quality and insufficient to determine effects on blood lead levels or clinical outcomes. This review focused on evidence of screening and treatment of individuals in primary care settings. Community or public healthbased approaches are other important strategies used to address lead exposures. Risk factors for lead exposure include socioeconomic disadvantage, living near lead industry, renovation or deterioration of older lead-painted houses, poor nutrition, and previously living in countries where leaded gasoline is used. 2, 45, 46 Exposures may occur through water sources, lead pipes, or culturally linked sources, such as folk remedies, imported food and candy, and traditional pottery used for cooking. 47, 48 The CDC recommends that public health entities provide clinicians with community-specific risk factors that can be used to determine the need for screening.
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Elevated blood lead levels predominantly affect socioeconomically disadvantaged and minority children. Different sources of lead exposure than have been previously considered are emerging in these children, yet research on screening and prevention in these populations remains limited.
47,48,50 Exposures related to community water sources, lead pipes in schools, and factory emissions affecting neighborhood soil quality are some of the relevant factors not captured by current screening questionnaires. Culturally linked sources of lead poisoning, such as imported candy, pottery, traditional medicines, and cosmetics, specific to subpopulations 47,48 living in the United States also may pose additional risk, since little regulation exists to monitor, identify, and control these nonpaint exposures. Additional research is warranted to validate these potential associations in specific geographic locations. Children exposed to less common sources of lead exposure may live in areas with a higher risk for housing-related source exposures. 50 The dual risk associated with these communities suggests a more focused strategy to deal with population-specific risks. Elevated blood lead levels are associated with serious, often irreversible, health consequences. Effective screening could identify leadcontaminated residential environments and abate them, not only to improve the health of the individual child but also of others in the household. While remediation of lead exposures in a specific residence may be too late for an individual child who already is exposed, the downstream effect could prevent exposure for subsequent generations of children. Development of questionnaires that incorporate current risk factors for elevated lead levels with validation in contemporary populations of children in the United States is necessary. Research evaluating effectiveness of treatments for elevated lead levels, such as counseling, nutritional interventions, and residential lead hazard control techniques, in trials with adequate sample sizes may also inform treatment strategies. While there is limited evidence on the clinical benefit of nutritional supplementation in reducing lead levels in children, epidemiologic evidence suggests potential benefits and is supported by studies of the toxicokinetics of lead in childhood. Effects of nutrition could be further validated by well-designed research studies. Ideally, randomized trials would recruit children from a range of racial, ethnic, and socioeconomic strata and evaluate the effects of screening on improving health outcomes as well as short-and long-term harms. However, ethical issues of trials in the context of environmental health exposures would limit feasibility. Research on newer methods for testing blood lead levels, such as point-of-care testing, and on the intraindividual and interlaboratory reliability of blood lead level testing would be helpful for informing testing strategies.
Limitations
This review has several limitations. First, there was an overall lack of evidence to address all key questions. Second, despite searching for updated data, the available studies evaluating the effectiveness of the risk-based questionnaires were published between 1994 and 2003 and may not assess contemporary risk factors. Current clinical practice uses a reference blood lead level greater than 5 μg/dL based on updated CDC guidance, but several of the studies included for this review used the older reference value of 10 μg/dL or greater. Third, nonrandomized studies were included to evaluate the effectiveness of interventions for elevated blood levels but are more susceptible to confounding and bias, leading to downgrading of study quality. Fourth, direct correlation of environmental exposures with longer-term health outcomes is difficult to study and characterize, since these exposures often have subtle clinical effects. Fifth, the review focused on screening and treatment of individuals in primary care settings, excluding community and public health approaches that could inform screening practices at the population level.
Conclusions
Screening questionnaires were not accurate for identifying children with elevated blood lead levels. Chelating agents in children were not associated with sustained effects on blood level levels but were associated with harms. Role of the Funder/Sponsor: Investigators worked with USPSTF members and AHRQ staff to develop the scope, analytic framework, and key questions for this review. AHRQ had no role in study selection, quality assessment, or synthesis. AHRQ staff provided project oversight, reviewed the report to ensure that the analysis met methodological standards, and distributed the draft for peer review. Otherwise, AHRQ had no role in the conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, 
Criteria for Assessing Internal Validity of Individual Studies
The Methods Work Group for the US Preventive Services Task Force (USPSTF) developed a set of criteria by which the internal validity of individual studies could be evaluated. The USPSTF accepted the criteria, and the associated definitions of quality categories, that relate to internal validity at its September 1999 meeting.
This appendix describes the criteria relating to internal validity and the procedures that topic teams follow for all updates and new assessments in making these judgments.
All topic teams use initial "filters" to select studies for review that deal most directly with the question at issue and that are applicable to the population at issue. Thus, studies of any design that use outdated technology or that use technology that is not feasible for primary care practice may be filtered out before the abstraction stage, depending on the topic and the decisions of the topic team. The teams justify such exclusion decisions if there could be reasonable disagreement about this step. The criteria below are meant for those studies that pass this initial filter. Presented below are a set of minimal criteria for each study design and then a general definition of three categories: "good," "fair," and "poor," based on those criteria. These specifications are not meant to be rigid rules but rather are intended to be general guidelines, and individual exceptions, when explicitly explained and justified, can be made. In general, a "good" study is one that meets all criteria well. A "fair" study is one that does not meet (or it is not clear that it meets) at least one criterion but has no known "fatal flaw." "Poor" studies have at least one fatal flaw.
Systematic Reviews
Criteria:
• Comprehensiveness of sources considered/search strategy used.
• Standard appraisal of included studies.
• Validity of conclusions.
• Recency and relevance are especially important for systematic reviews.
Definition of ratings from above criteria:
Good: Recent, relevant review with comprehensive sources and search strategies; explicit and relevant selection criteria; standard appraisal of included studies; and valid conclusions.
Fair: Recent, relevant review that is not clearly biased but lacks comprehensive sources and search strategies.
Poor: Outdated, irrelevant, or biased review without systematic search for studies, explicit selection criteria, or standard appraisal of studies.
Randomized Controlled Trials and Cohort Studies
• Initial assembly of comparable groups:
• For RCTs: adequate randomization, including first concealment and whether potential confounders were distributed equally among groups.
• For cohort studies: consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts.
• Maintenance of comparable groups (includes attrition, cross-overs, adherence, contamination).
• Important differential loss to follow-up or overall high loss to follow-up.
• Measurements: equal, reliable, and valid (includes masking of outcome assessment).
• Clear definition of interventions.
• All important outcomes considered.
• Analysis: adjustment for potential confounders for cohort studies, or intention to treat analysis for RCTs.
Definition of ratings based on above criteria:
Good: Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (follow-up at least 80 percent); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention to confounders in analysis. In addition, for RCTs, intention to treat analysis is used.
Fair: Studies will be graded "fair" if any or all of the following problems occur, without the fatal flaws noted in the "poor" category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred with follow-up; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention to treat analysis is done for RCTs.
Poor: Studies will be graded "poor" if any of the following fatal flaws exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied at all equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. For RCTs, intention to treat analysis is lacking. Guidelines emphasize primary prevention of lead poisoning and recommend that clinicians educate families about prevention of lead exposure and provide environmental assessments to identify sources of lead exposure before testing children for lead poisoning. 
Organization
